CRNX
Price:
$50.39
Market Cap:
$4.03B
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsu...[Read more]
Industry
Biotechnology
IPO Date
2018-07-18
Stock Exchange
NASDAQ
Ticker
CRNX
According to Crinetics Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -13.40. This represents a change of 27.19% compared to the average of -10.54 of the last 4 quarters.
The mean historical PE Ratio of Crinetics Pharmaceuticals, Inc. over the last ten years is -18.88. The current -13.40 PE Ratio has changed 7.00% with respect to the historical average. Over the past ten years (40 quarters), CRNX's PE Ratio was at its highest in in the June 2023 quarter at -4.80. The PE Ratio was at its lowest in in the June 2017 quarter at -51.60.
Average
-18.88
Median
-11.24
Minimum
-56.51
Maximum
-5.90
Discovering the peaks and valleys of Crinetics Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 73.54%
Maximum Annual PE Ratio = -5.90
Minimum Annual Increase = -63.85%
Minimum Annual PE Ratio = -56.51
Year | PE Ratio | Change |
---|---|---|
2023 | -9.63 | 61.95% |
2022 | -5.95 | -41.88% |
2021 | -10.23 | 73.54% |
2020 | -5.90 | -51.85% |
2019 | -12.24 | -8.82% |
2018 | -13.43 | -63.85% |
2017 | -37.15 | -34.27% |
The current PE Ratio of Crinetics Pharmaceuticals, Inc. (CRNX) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
-8.60
5-year avg
-8.79
10-year avg
-18.88
Crinetics Pharmaceuticals, Inc.’s PE Ratio is less than Viridian Therapeutics, Inc. (-3.95), less than Cytokinetics, Incorporated (-10.84), greater than Structure Therapeutics Inc. (-18.15), less than Icosavax, Inc. (-8.27), less than Passage Bio, Inc. (0), less than REGENXBIO Inc. (-0.57), less than LianBio (-2.41), less than Kezar Life Sciences, Inc. (-0.39), less than Inhibrx, Inc. (-0.41), less than Merus N.V. (0.13), greater than Lyell Immunopharma, Inc. (-18.45), less than Kronos Bio, Inc. (-1.42), less than Black Diamond Therapeutics, Inc. (-0.58), less than TCR2 Therapeutics Inc. (-3.70), less than Harpoon Therapeutics, Inc. (-0.44), less than Alector, Inc. (-2.94), less than null (-2.92),
Company | PE Ratio | Market cap |
---|---|---|
-3.95 | $900.21M | |
-10.84 | $6.36B | |
-18.15 | $2.11B | |
-8.27 | $769.04M | |
0 | $43.48M | |
-0.57 | $567.38M | |
-2.41 | $34.47M | |
-0.39 | $40.82M | |
-0.41 | $218.01M | |
0.13 | $3.41B | |
-18.45 | $299.52M | |
-1.42 | $59.36M | |
-0.58 | $305.13M | |
-3.70 | $58.11M | |
-0.44 | $865.08M | |
-2.94 | $472.01M | |
-2.92 | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Crinetics Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Crinetics Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Crinetics Pharmaceuticals, Inc.'s PE Ratio?
How is the PE Ratio calculated for Crinetics Pharmaceuticals, Inc. (CRNX)?
What is the highest PE Ratio for Crinetics Pharmaceuticals, Inc. (CRNX)?
What is the 3-year average PE Ratio for Crinetics Pharmaceuticals, Inc. (CRNX)?
What is the 5-year average PE Ratio for Crinetics Pharmaceuticals, Inc. (CRNX)?
How does the current PE Ratio for Crinetics Pharmaceuticals, Inc. (CRNX) compare to its historical average?